ONCBeiGeneRunning, no new patients
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Urothelial Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 420 (final count)
- Started
- May 29, 2019
- Main results expected
- Jun 30, 2027
- Fully finished
- Oct 21, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall survival (OS) in the Intent to Treat (ITT) set
Measured over: From first randomization up to 3.5 years, approximately
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03967977 · record last updated 2026-06-22 · checked 2026-11-09 15:47 UTC